BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

Overview Fund Trends Analyst Outlook Journalist POV

25 hedge funds and large institutions have $5.97M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less call options, than puts

Call options by funds: $ | Put options by funds: $

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

Holders
25
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$3.2M
Puts
$4.3M
Net Calls
Net Calls Change

Top Buyers

1
+$447K
2
+$440K
3
+$16.2K

Top Sellers

1
-$2.53M
2
-$1.59M
3
-$1.02M
4
BRC
Bell Rock Capital
Delaware
-$678K
5
Koshinski Asset Management
Koshinski Asset Management
Illinois
-$263K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
–
27
–
28
–
29
–
30
–
31
–
32
–
33
–
34
–
35
–
36
–
1
2